Cipla
Update in progressCIPLA.NS (NSE)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
Cipla Limited and its subsidiaries develop, manufacture, and distribute pharmaceutical products in India, the United States, South Africa, and worldwide. Operating through Pharmaceuticals and New Ventures, it offers generic and branded medicines, vaccines, active pharmaceutical ingredients, and formulations for a wide range of therapeutic areas. The company also focuses on consumer health, biosimilars, and specialty segments, and is based in Mumbai, founded in 1935.
Company score
- Sentiment
- 0.06
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.15
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 1.18
- Governance
- 0.06
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.41
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.23
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNSE (NSI)
- LocationIndia
- CEOMr. Achin Gupta
- Founded1935
- Employees31,369
- Websitewww.cipla.com
Identifiers
- ISININE059A01026